Shengjing Hospital Affiliated to China Medical University
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation | Arrhythmias, Cardiac, Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, atrial fibrillation, cardiovascular disorder, heart disorder, vascular disorder | Recruiting | Not applicable | 2026-03-04 | NCT06871228 | |
| A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-15 | NCT07124936 | |
| SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer | HR Positive/HER2 Low Breast Cancer | Recruiting | Phase 2 | 2024-12-04 | NCT06340230 | |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | HER2-positive Breast Cancer | Active, not recruiting | Phase 2 / Phase 3 | 2024-10-30 | NCT05426486 | |
| To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection | hypogonadotropic hypogonadism 7 with or without anosmia | Not yet recruiting | Phase 3 | 2024-08-20 | NCT06561594 | |
| A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2024-07-05 | NCT05635487 | |
| Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2022-09-13 | NCT04983121 | |
| Psychological Screening and Nursing of Twin Pregnancy | Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, pregnancy disorder | Recruiting | Not applicable | 2022-01-19 | NCT05182541 | |
| Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 3 | 2021-07-22 | NCT04973319 | |
| Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2021-07-20 | NCT04476485 |